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A new inhibitor of the b-arrestin/AP2 endocytic
complex reveals interplay between GPCR
internalization and signalling
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In addition to G protein-coupled receptor (GPCR) desensitization and endocytosis, b-arrestin
recruitment to ligand-stimulated GPCRs promotes non-canonical signalling cascades.
Distinguishing the respective contributions of b-arrestin recruitment to the receptor and
b-arrestin-promoted endocytosis in propagating receptor signalling has been limited by the
lack of selective analytical tools. Here, using a combination of virtual screening and cell-based
assays, we have identiﬁed a small molecule that selectively inhibits the interaction between
b-arrestin and the b2-adaptin subunit of the clathrin adaptor protein AP2 without interfering
with the formation of receptor/b-arrestin complexes. This selective b-arrestin/b2-adaptin
inhibitor (Barbadin) blocks agonist-promoted endocytosis of the prototypical b2-adrenergic
(b2AR), V2-vasopressin (V2R) and angiotensin-II type-1 (AT1R) receptors, but does not
affect b-arrestin-independent (transferrin) or AP2-independent (endothelin-A) receptor
internalization. Interestingly, Barbadin fully blocks V2R-stimulated ERK1/2 activation and
blunts cAMP accumulation promoted by both V2R and b2AR, supporting the concept of
b-arrestin/AP2-dependent signalling for both G protein-dependent and -independent
pathways.
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B
eta-arrestins (b-arrestin1 and b-arrestin2) play central roles
in the mechanisms regulating G protein-coupled receptor
(GPCR) signalling and trafﬁcking1,2. The recruitment of
b-arrestin to phosphorylated activated GPCRs at the plasma
membrane, following sustained agonist stimulation, promotes
desensitization by functionally uncoupling the activated receptors
from their heterotrimeric G proteins3. Complexes formed
between ligand-occupied GPCRs and b-arrestin are then
directed to the endocytic machinery, leading to their interaction
with clathrin and its adaptor protein AP2, followed by the
internalization of the receptors4–6. Once internalized and targeted
to early endosomes, receptors can either be recycled back to the
plasma membrane or targeted toward lysosomal degradation. The
fate of the endocytosed receptors has been inferred to depend
largely on the stability of the interaction between the internalized
receptor and b-arrestin7; where the more labile complexes lead to
rapid recycling of receptor, whereas more stable interactions
prevent recycling and favour receptor degradation. Although
endocytosis was ﬁrst linked to receptor desensitization and
resensitization, more recent evidence suggest that internalized
receptors can engage in various signalling activities8,9.
For instance, endocytosis has been linked to the b-arrestin-
dependent activation of mitogen-activated protein kinases
(MAPK)10 and the sustained activation of adenylyl-cyclase by
some receptors11–13. Despite the well-established contribution of
b-arrestins in various steps of receptor trafﬁcking and signalling,
spatial and temporal causative links between these responses have
remained difﬁcult to probe, mainly because of the lack of selective
pharmacological tools.
Several endocytic paths have been described for GPCRs,
including both clathrin-dependent and -independent events14,15,
with the vast majority of GPCRs undergoing b-arrestin-
dependent, clathrin-mediated endocytosis. Upon binding to
agonist-bound receptor, b-arrestin undergoes a major
conformational change, adopting an active conformation that is
characterized by the release of its C-terminus, which is buried in
its polar core16. The exposed b-arrestin C-tail constitutes an
accessible site (DxxFxxFxxxR motif) for the binding of the
b2-adaptin subunit of the AP2 complex, which directs the
receptor/b-arrestin complexes into maturing clathrin-coated pits
(CCPs)17,18. A tripartite interaction exists between b-arrestin,
AP2 and clathrin in CCPs (that is, each protein involved in a
direct interaction with the other two proteins) and the interaction
between b-arrestin and AP2 is an important initial step in
localizing GPCRs into the CCP, following agonist stimulation17.
The structural determinants for b-arrestin and AP2
interaction have been well-deﬁned17,19, and more recently
validated by a co-crystal between the b2-adaptin subunit of
AP2 and a peptide fragment of b-arrestin1 C-terminus20.
Most of our knowledge concerning GPCR endocytosis and
b-arrestin-dependent signalling has been gained through
mutagenesis and protein depletion studies in particular for
b-arrestins, which would indiscriminately affect recruitment
of b-arrestin to receptors, desensitization, endocytosis and
b-arrestin-mediated signalling21–23. Speciﬁc pharmacological
probes targeting b-arrestin/AP2 complexes would be invaluable
for determining the role of this complex and clathrin-mediated
endocytosis in GPCR signalling.
In this light, we have used a virtual screening approach to
identify speciﬁc inhibitors of b-arrestin/AP2 complexes. For this
purpose, we took advantage of a well-deﬁned groove within the
b2-adaptin ear platform subdomain, which accommodates the
carboxyl-tail of b-arrestin20, hence providing a putative site for a
small molecule interfering with the b-arrestin/AP2 interaction.
On the basis of this structural insight, we combined virtual
screening with a sensitive bioluminescence resonance energy
transfer (BRET)-based assay24 to identify and validate novel
inhibitors of the b-arrestin/b2-adaptin interaction. From ﬁve
compounds found to modulate the b-arrestin/b2-adaptin
interaction, two were inhibitors and one of them, which we
named b-arrestin/b2-adaptin interaction inhibitor (Barbadin),
was further characterized and used as a tool to study the interplay
between receptor GPCR internalization and signalling.
Results
Screening for a b-arrestin/b2-adaptin interaction inhibitor.
To identify candidate inhibitors of the b-arrestin/b2-adaptin
interaction, we ﬁrst performed a structure-based virtual screen
through the use of molecular docking calculations (Fig. 1a, and
methods). We took advantage of the available coordinates of the
crystal structure of a complex between the b2-adaptin ear domain
of the clathrin adaptor protein AP2 and a C-terminal peptide of
b-arrestin1 (PDB entry 2IV8) (ref. 20). In this complex, the
b-arrestin peptide is situated in a groove located in the
b2-adaptin ear platform subdomain, where Phe-388, Phe-391
and Arg-395 from b-arrestin1 interact with key Glu-849, Tyr-888
and Glu-902 residues of b2-adaptin. The virtual screen was
performed using a region of the b2-adaptin ear platform that
included the entire binding groove as the target, and the
Myriascreen diversity collection of 10,000 compounds selected
for their structural diversity and drug-likeness from an original
chemical library of 300,000 molecules. Subsequently to docking
calculations, the poses of the best-ranked molecules based on
predicted binding energy (196 compounds) were visually
inspected to select the candidates that make favourable
interactions with residues from the b2-adaptin groove, reported
to be critical for b-arrestin binding19. Among these best
candidates, 52 compounds were selected based on availability
criteria. The list of these compounds with their acquisition
number is presented in Supplementary Table 1.
To assess the ability of the 52 compounds to affect the
b-arrestin/b2-adaptin interaction, we used a BRET-based assay
that directly monitors the interaction between these two proteins
following agonist-stimulation of GPCRs (ref. 24). The vasopressin
type-2 receptor (V2R), that was previously shown to promote a
large BRET increase between b-arrestin1-RlucII and b2-adaptin-
YFP upon arginine vasopressin (AVP) stimulation24 (Fig. 1b),
was chosen as receptor model for the screen. Before assessing the
ability of the 52 compounds to modulate the BRET between
b2-adaptin-YFP and b-arrestin1-RlucII, we veriﬁed whether the
molecules could spectrally interfere with BRET measurements.
When tested in HEK293 cells overexpressing either the
b-arrestin1-RlucII or the b2-adaptin-YFP alone, 11 of the 52
compounds that had a signiﬁcant effect on either luminescence or
ﬂuorescence signals were discarded (Supplementary Fig. 1).
The remaining 41 compounds were tested in live cells, using
the aforementioned BRET-based assay in which the V2R,
b2-adaptin-YFP and b-arrestin1-RlucII were co-expressed. As
shown in Fig. 1c, ﬁve compounds signiﬁcantly modulated the
AVP-promoted BRET. Compounds #14, #19 and #20 potentiated,
whereas compounds #33 and #42 inhibited the AVP-promoted
BRET between b2-adaptin-YFP and b-arrestin1-RlucII.
Compounds #14, #19 and #20 might favour the interaction
between b-arrestin1 and b2-adaptin, or modify the complex in a
way that brings the YFP and RlucII moieties closer, or in an
orientation which is more permissive for energy transfer.
Although they may be interesting molecules in their own rights,
we focused on characterizing compounds #33 and #42 because
we sought to identify inhibitors of the b2-adaptin/b-arrestin
complex.
To assess the potency of these compounds, concentration-
response curves of the inhibitory actions of the compounds on
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the V2R-stimulated b-arrestin/b2-adaptin interaction were
carried out. In addition to compounds #33 and #42, compound
#1 was included in the analysis as a negative control (Fig. 2a–c).
As expected, #1 was completely inactive even at the highest
concentration used (Fig. 2a), whereas both #33 and #42 showed
concentration-dependent inhibitory responses. While #33 had a
low-potency (450 mM) that was difﬁcult to estimate with
precision due to incomplete inhibition curve (Fig. 2b), #42
showed a well-deﬁned sigmoidal inhibitory curve yielding an
estimated IC50 of 19.1 mM for b-arrestin1 (Fig. 2c) and 15.6 mM
for b-arrestin2 (Supplementary Fig. 2a). Compound #42,
which structure is shown in Fig. 2d, represented a validated hit
for a potential inhibitor of the complex and hence named
Barbadin, and further characterized at the expense of #33 that
showed lower potency. First, the reversible mode of action of
Barbadin was assessed by incubating cells with Barbadin
for 30min and monitoring BRET between b2-adaptin and
b-arrestin1 following, or not, extensive wash before AVP
stimulation. As shown in Supplementary Fig. 2b, the washing
procedure completely prevented the action of Barbadin
demonstrating its reversibility.
To further investigate the potential binding mode of Barbadin
on AP2, we examined the docking poses obtained for this
compound. The docking calculations resulted in a single best
pose, based on its prevalence among the possible solutions and
the lowest binding energy that positioned Barbadin within the
groove of the b2-adaptin platform subdomain (Fig. 2e). The
benzylphenyl moiety of Barbadin tightly ﬁts a hydrophobic
pocket lined mainly by Phe-837, Leu-838, Ile-876, Ala-877 and
Tyr-888, via a set of non-polar and p–p aromatic interactions.
Superimposition of the docking pose of Barbadin with the
b2-adaptin/b-arrestin C-tail co-crystal structure suggests that
both phenyl rings of Barbadin are adopting very similar binding
modes as both b-arrestin’s key Phe-391 and Phe-395 residues
(Fig. 2f). The thieno-pyrimidinone moiety interacts through p–p
aromatic interactions with Trp-841, and also through a network
of two hydrogen bonds involving Tyr-888 and Glu-902 (Fig. 2e),
two residues of b2-adaptin shown to be critical for the binding of
b-arrestin19. To investigate the role of the benzylphenyl moiety in
Barbadin’s inhibitory activity, we conducted a preliminary
structure-activity relationship study with four analogues of
Barbadin. As shown in Supplementary Fig. 3, a branched
aliphatic and/or extended phenyl group on Barbadin’s thieno-
pyrimidinone core is essential for its inhibitory action, consistent
with the docking pose.
In addition, to assess the direct binding of Barbadin to
b2-adaptin we performed a thermal-shift assay using puriﬁed
appendage domain of b2-adaptin (b2-appendage, amino-acids
with sequence: 700–937). The stability curves obtained in Fig. 2g
show that, similarly to a 20-mer b-arrestin C-tail peptide known
to bind to the b-appendage20, Barbadin promoted a dose-
dependent rightward shift of the melting temperature consistent
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Figure 1 | Screen for inhibitors of the interaction between b2-adaptin and b-arrestin. (a) Flowchart outlining the steps of the virtual screening and the
selection of candidate molecules to be tested. (b) Schematic representation and dynamic range of the BRET-based assay used to test the compounds
selected from the virtual screen that monitors the b2-adaptin/b-arrestin1 interaction. HEK293T cells were transfected with b2-adaptin-YFP, b-arrestin1-
RlucII and myc-V2R. BRET was measured following V2R stimulation with 100nM AVP for 45min. Data are the mean±s.e.m. of three independent
experiments. Statistical analysis was performed using a paired Student’s test (***Po0.001). (c) b2-adaptin/b-arrestin1 interaction was assessed as
described in (b) with AVP-stimulation following pre-incubation with the indicated compounds (100mM) for 25min. Data are the mean±s.e.m. of three
independent experiments. One-way ANOVA followed by Tuckey’s post-hoc tests were used to assess the statistical signiﬁcance of the compound-induced
BRET modulation compared to DMSO (***Po0.001).
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with a stabilization of the b-appendage due to the direct binding
of the compound.
Barbadin selectively inhibits the b-arrestin/AP2 interaction. To
rule out the possibility that Barbadin interferes directly at the
level of the V2R, we assessed its effect on the b-arrestin1/
b2-adaptin interaction by BRET, promoted by two additional
GPCRs, the b2-adrenergic receptor (b2AR) and the angiotensin-
II type-1 receptor (AT1R) (Fig. 3a–c). As was the case for the
V2R, Barbadin inhibited the BRET between b-arrestin1-RlucII
and b2-adaptin-YFP promoted by the activation of both
receptors. The b2AR was selected because it differs from the V2R
and AT1R in its mode of interaction with the b-arrestins7. The
b2AR is classiﬁed as a class A receptor, interacting transiently
with b-arrestins and rapidly recycling back from the endosomes
to the cell surface, whereas V2R and AT1R are class B receptors
forming tighter receptor/b-arrestin complexes that reside for
longer times in endosomes before being targeted to lysosomal
degradation. These observations strongly suggest that the
inhibition occurs at the level of the b-arrestin/b2-adaptin
interaction and is not a receptor speciﬁc effect.
We next evaluated the mode of action of Barbadin by testing its
effect on the other isoform of b-arrestin, b-arrestin2, that is
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Figure 2 | Identiﬁcation of Barbadin (compound #42) as an inhibitor of the interaction between b2-adaptin and b-arrestin. (a–c) Concentration-
response curves of compounds #1, #33 and #42 selected from the BRET-based screen (Fig. 1) using the same b2-adaptin/b-arrestin1 interaction assay.
Dotted line represents the level of AVP-promoted BRET upon pre-incubation with DMSO. Data are the mean±s.e.m. of three independent experiments.
(d) Chemical structure of Barbadin (IUPAC name: 3-amino-5-(4-benzylphenyl)-3H,4H-thieno[2,3-d]pyrimidin-4-one). (e,f) Docking pose of Barbadin
(green sticks) within the groove of b2-adaptin platform subdomain (grey ribbon (e), or surface (f)) that is the site of interaction with b-arrestin (orange
ribbon and sticks (f)). b2-adaptin residues known to interact with b-arrestin are labelled and shown as grey stick. Hydrogen-bonds interactions between
Barbadin and both Tyr-888 and Glu-902 are depicted as magenta dotted lines (e). Superimposition of Barbadin with the b-arrestin1 C-terminus peptide
as in the co-crystal structure (PDB entry 2IV8), where Phe-388, Phe-391 and Arg-395 are the three key residues for b-arrestin binding interaction
(shown from top to bottom as orange sticks) (f). (g) Thermal denaturation of b2-adaptin (residues 700–937) and concentration-dependent stabilization
effect of Barbadin. The maximum of the ﬁrst derivatives of ﬂuorescence (dF/dT) data from differential scanning ﬂuorimetry corresponds to the melting
temperatures (Tm, indicated with a dotted line) of b2-adaptin in the presence of DMSO, Barbadin or b-arrestin1 C-tail peptide (positive control) at the
indicated concentrations.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15054
4 NATURE COMMUNICATIONS | 8:15054 |DOI: 10.1038/ncomms15054 | www.nature.com/naturecommunications
highly homologous to b-arrestin1 and would be predicted to
interact with b2-adaptin in a similar manner. As shown in
Fig. 3a–c, Barbadin signiﬁcantly inhibited the interaction between
b2-adaptin and both b-arrestins after stimulation of V2R, b2AR
or AT1R. Moreover, the extent of inhibition was comparable,
in all cases Barbadin inhibiting the BRET signal by E50%. The
higher agonist-promoted signal observed for b-arrestin2 versus
b-arrestin1 upon b2AR stimulation, compared to the similar
signals measured for both b-arrestin isoforms following V2R or
AT1R stimulation, is consistent with the notion that class A,
but not class B receptors bind b-arrestin2 with greater avidity
than b-arrestin1 (refs 7,24).
To further assess whether Barbadin acts by selectively
inhibiting the interaction between b2-adaptin and b-arrestin,
and not by inhibiting the recruitment of b-arrestin to GPCRs,
the effect of Barbadin was also tested on the time-dependent
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GST-b2-adaptin were detected by western blot using anti-Flag and anti-clathrin (heavy chain) antibodies, respectively. Relative intensities were normalized
to the GST input for each condition and densitometry data are the mean±s.e.m. of three independent experiments and analysed using a two-way ANOVA
followed by Bonferroni’s post-hoc tests (NS, non-signiﬁcant; ***Po0.001).
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AVP-promoted BRET between either b2-adaptin-YFP and
b-arrestin1-RlucII or V2R-YFP and b-arrestin1-RlucII (Fig. 3d,e).
Barbadin strongly inhibited AVP-promoted BRET between
b-arrestin1 and b2-adaptin but was without effect on the
V2R/b-arrestin1 BRET induced upon AVP stimulation, thus
conﬁrming a selective action on the b-arrestin/b2-adaptin
complex. Similar results were obtained for the class A b2AR
(Supplementary Fig. 4a,b).
Fluorescence confocal microscopy conﬁrmed that Barbadin did
not inhibit the recruitment of b-arrestin2 to the plasma
membrane upon V2R activation (Supplementary Fig. 4c). In fact,
co-localization of V2R and b-arrestin2 at the plasma membrane
was more readily detected following Barbadin treatment as
compared to control conditions, consistent with the notion that it
does not affect receptor/b-arrestin interaction but that it inhibits
internalization of receptor/b-arrestin complexes, hence increasing
their accumulation at the plasma membrane.
The speciﬁcity of the effect of Barbadin on the endocytic
complex formation was also validated by co-immunoprecipitation
and GST pull-down experiments. Figure 3f illustrates
that Barbadin signiﬁcantly inhibited AVP-promoted
co-immunoprecipitation between endogenous b-adaptins and
b-arrestin1/2 but did not affect the association with epsin,
a protein interacting with lower afﬁnity than b-arrestin at a
different site on b2-adaptin’s ear platform subdomain25.
Similarly, Barbadin signiﬁcantly inhibited the ability of GST-b2-
adaptin to pull-down b-arrestin1 (Fig. 3g) but had no effect on
the pull-down of clathrin, which is known to interact at
b2-adaptin sites (the hinge region and the ear b-sandwich
subdomain) that are distinct from the interaction site of b-
arrestin. Taken together, these results indicate that Barbadin
selectively blocks the interaction between b-arrestin and
b2-adaptin as predicted by the in silico docking and the BRET-
based assays.
Barbadin blocks b-arrestin/AP2-dependent GPCR endocytosis.
Because the interaction between b-arrestins and b2-adaptin is
important for initiating receptor internalization, we next sought
to determine whether Barbadin could be used as a pharmacolo-
gical tool, to block the ligand-promoted endocytosis of GPCRs.
For this purpose, we used enhanced bystander BRET (ebBRET)
trafﬁcking sensors allowing to monitor both receptor dis-
appearance from the plasma membrane (rGFP-CAAX sensor,
Fig. 4a) and their accumulation in early endosomes (rGFP-FYVE,
Fig. 4e) in spectrometric and microscopy-based assays26. As
shown in Fig. 4a–h, Barbadin blocked the time-dependent
agonist-induced loss of V2R, b2AR and AT1R from the cell
surface (Fig. 4b–d), and consequently prevented their appearance
into early endosomes (Fig. 4f–h), demonstrating that it acts as an
efﬁcient endocytosis inhibitor. Notably, the IC50 for the inhibitory
action of Barbadin on endocytosis are similar to those observed
for its action on the b-arrestin/AP2 interaction (Fig. 2c and
Supplementary Fig. 2a), consistent with its mode of action
(Supplementary Fig. 5a–h). The effect of Barbadin on endocytosis
was further conﬁrmed using BRET-microscopy allowing to image
receptor localization at the plasma membrane (Fig. 4i and
Supplementary Fig. 5i), and in early endosomes (Supplementary
Fig. 5j), coherent with the spectrometric measurements
(Fig. 4b–d,f–h).
To orthogonally validate the BRET-based endocytosis mea-
surements, we used ﬂow-cytometry (FACS) with double-tagged
receptors where a HA epitope and a Venus ﬂuorescent protein are
fused to amino- and carboxy-termini, respectively, allowing to
monitor both cell surface (HA immunoﬂuorescence) and total
receptor (venus ﬂuorescence) expression27. As shown in Fig. 5a–
c, agonist stimulation of cells expressing either the V2R or b2AR
led to a time-dependent disappearance of cell surface signals
corresponding to agonist-promoted endocytosis. Barbadin
signiﬁcantly inhibited FACS-monitored endocytosis to extents
comparable to Pitstop2 and Dyngo-4a, two known inhibitors
of both clathrin-dependent and independent endocytosis28–30
(Fig. 5a–c). Since both b2AR and V2R are known to undergo
b-arrestin and b2-adaptin-dependent endocytosis, the effect of
Barbadin on agonist-promoted endocytosis is likely explained by
the inhibitory action of Barbadin on the b-arrestin/b2-adaptin
interaction. To further validate this mode of action, we used
the type A endothelin receptor (ETAR) that undergoes
b-arrestin-dependent but clathrin-independent endocytosis into
caveolae31, and which involves the recruitment of b-arrestin to
the receptor without engagement of AP2 (ref. 24). As predicted
from its proposed mode of action, Barbadin did not
inhibit endothelin-promoted ETAR endocytosis (Fig. 5d). In
contrast, Pitstop2 signiﬁcantly blocked agonist-stimulated ETAR
endocytosis consistent with its clathrin-independent action29.
To further assess Barbadin selectivity, we tested its effect on
transferrin endocytosis occurring through clathrin-coated pits
and involving the transferrin receptor (TfR), a non-GPCR that
interacts directly with AP2 independently of b-arrestin32.
Barbadin did not signiﬁcantly inhibit the internalization of
transferrin at any of the time points examined, whereas it was
blocked by Pitstop2 as early as 2min after stimulation (Fig. 5e,f).
The ability of Barbadin to block the endocytosis of natively
expressed GPCR was also conﬁrmed by monitoring the agonist-
promoted loss of AT1R from cell surface using radio-ligand
binding in vascular smooth muscle cells (Supplementary Fig. 6).
Taken together, these results indicate that Barbadin is a suitable
tool to study b-arrestin/AP2-dependent endocytosis.
To gain insight on the inhibitory properties of Barbadin on
clathrin-mediated internalization of GPCRs, we next examined
the sub-cellular distribution of b-arrestin, AP2 and clathrin by
confocal ﬂuorescence microscopy in V2R-expressing cells
(lacking endogenous b2-adaptin to facilitate the incorporation
of CCPs-labelled b2-adaptin into AP2 complexes, Supplementary
Fig. 7a) transfected with b-arrestin2-mCherry, b2-adaptin-CFP
and clathrin-light-chain-YFP. As shown in Fig. 6a, under basal
conditions b2-adaptin and clathrin colocalized in CCPs,
whereas b-arrestin is diffuse in the cytosol. On AVP stimulation,
b-arrestin translocates to CCPs where it colocalizes with
b2-adaptin and clathrin (Fig. 6a,b). A pre-treatment of 30min
with Barbadin did not disrupt the CCPs nor prevented the
translocation of b-arrestin to pits (Fig. 6b). In fact, Barbadin led
to an increase in b-arrestin/b2-adaptin colocalization
(Supplementary Fig. 7b,c) that was even more evident upon
longer agonist stimulation (Fig. 6c). The maintenance of the
CCPs integrity upon Barbadin treatment is consistent with our
previous biochemical data showing that Barbadin has no
signiﬁcant effect on the binding of clathrin to b2-adaptin
(Fig. 3g). The observation that b-arrestin translocation to the
plasma membrane is not inhibited by Barbadin is also in
agreement with our BRET data demonstrating that Barbadin does
not interfere with the recruitment of b-arrestin to V2R (Fig. 3e)
or b2AR (Supplementary Fig. 4b). Although, the lack of obvious
inhibition of b-arrestin and b2-adaptin colocalization by
Barbadin appears counter-intuitive considering it blocks the
interaction between these two proteins, the localization of b-
arrestin to the pits does not result exclusively from its interaction
with b2-adaptin. Indeed, many other protein–protein interactions
have been implicated in stabilizing GPCR/b-arrestin complexes at
the PM and into CCPs, including direct binding of b-arrestin’s
N-terminal domain33 to the m-subunit of AP2 and an indirect
clathrin-mediated link between AP2 and b-arrestin’s C-terminal
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domain34,35. Therefore, the persistence of b-arrestin in CCPs and
its colocalization with AP2 in the presence of Barbadin most
likely reﬂects b-arrestin’s ability to directly interact with other
components of the CCPs, in particular clathrin itself bringing it in
close proximity to b2-adaptin, resulting in colocalization, without
a direct interaction. To further test this possibility, we took
advantage of a mutant form of b-arrestin lacking the major site of
interaction with clathrin (b-arrestin2-DClath). As shown in
Supplementary Fig. 7d, although b-arrestin2-DClath was still
recruited into CCPs, where it largely colocalized with b2-adaptin
upon AVP stimulation, Barbadin treatment resulted in a marked
reduction of b-arrestin2-DClath clustering in these CCPs as can
be seen by its more diffuse distribution at, or near, the PM, and
the reduced colocalization of the mutant b-arrestin with
b2-adaptin. These ﬁndings are consistent with the notion that
even though the interaction between b-arrestin and AP2 plays a
critical role for clustering receptor/b-arrestin complexes in CCPs,
other interactions such as the ones with clathrin are also
important, and that inhibiting only one of them is insufﬁcient
to prevent its targeting to CCPs. Yet, Barbadin clearly inhibited
the trafﬁc of b-arrestin from the plasma membrane to endosomes
that is seen upon sustained agonist stimulation of receptor
(Fig. 6c). This suggests that destabilizing the interaction
between the b2-adaptin and b-arrestin with Barbadin delays
CCPs-mediated internalization kinesis.
Barbadin modulates GPCR signalling. Several studies have
suggested a role for b-arrestin and/or endocytosis in downstream
signalling. Since Barbadin blocks b-arrestin/b2-adaptin
interaction and the subsequent endocytosis without affecting the
recruitment of b-arrestin to the receptor (Fig. 3d), it represents a
unique tool to selectively assess the role of b-arrestin/b2-adaptin-
dependent endocytosis in signalling. Given that b-arrestin-
mediated endocytosis has been proposed to contribute to the
activation of the MAPK by many GPCRs36,37 including the
V2R for which the ERK1/2 activation in HEK293 cells is entirely
barr-dependent38, we assessed the effect of Barbadin on the
V2R-stimulated ERK1/2 activity. As shown in Fig. 7a,c, Barbadin
completely blocked the AVP-stimulated ERK1/2 activation. This
effect was selective since Barbadin did not block EGF-stimulated
ERK1/2 (Fig. 7b,c). These data indicate that the engagement of
b2-adaptin by b-arrestin is essential for the b-arrestin-dependent
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activation of ERK1/2 by V2R and are consistent with a role for
endocytosis in this signalling cascade. When considering the
G protein-dependent signalling cascades such as the activation of
adenylyl cyclase, the b-arrestin-promoted endocytosis has been
proposed to contribute both to the desensitization-resensitization
cycle2,39, as well as sustained endosomal Gs signalling11–13. As
shown in Fig. 7d,e, Barbadin signiﬁcantly blunted the time-
dependent increase in cyclic AMP (cAMP) production promoted
by the agonist stimulation of either V2R or b2AR. This effect was
concentration-dependent yielding an IC50 ofB7.9 mM (Fig. 7g,h),
which is consistent with the potency of Barbadin to inhibit the
b-arrestin/b2-adaptin interaction (Fig. 2c). The selectivity of
action is conﬁrmed by the lack of effect of Barbadin on the
forskolin-stimulated cAMP production (Fig. 7i) or the activation
of Gs as measured by BRET (ref. 40) (Fig. 7f). Such inhibition of
the b2AR-stimulated cAMP production could result from the
lack of recycling of resensitized receptor to the plasma membrane
that normally follows endocytosis. However, the latter
explanation is unlikely because, in contrast to b2AR, V2R does
not recycle back to the plasma membrane following endocytosis,
and therefore this process would not contribute to the inhibition
of V2R-stimulated cAMP production observed here. These results
therefore indicate, as was recently suggested for some receptors,
that inhibition of endocytosis may prevent the adenylyl cyclase
signalling that persists following endocytosis11,12.
Discussion
The present study led to the identiﬁcation of the ﬁrst chemical
probe that speciﬁcally inhibits the interaction between b-arrestin
and the b2-adaptin subunit of AP2. We validated the important
role of this interaction for receptor endocytosis by demonstrating
that Barbadin blunts clathrin-mediated endocytosis of three
prototypical GPCRs (b2AR, V2R and AT1R) without interfering
with the translocation of b-arrestin to the receptor, nor with the
interaction of AP2 with other components of the endocytic
machinery. When used to dissect the role of the b-arrestin/AP2
interaction in GPCR signalling, Barbadin was found to inhibit the
activation of ERK and cAMP production elicited by receptor
stimulation, demonstrating that the b-arrestin/AP2 complex
plays a role not only in receptor trafﬁcking but also in signalling.
This work also illustrates that virtual screening can successfully
identify small molecule inhibitors of protein–protein interactions.
Despite the fact that identifying protein–protein interface
inhibitors remains challenging due to the large surfaces of these
interfaces and their planar architecture, a number of successes
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have now been reported for protein complexes bearing favourable
quaternary architectures41,42. In this context, the fact that the
groove delineating the b-arrestin binding site on the b2-adaptin
ear platform subdomain is well-deﬁned19,20 undoubtedly
contributed to conduct reliable docking calculations that led to
the identiﬁcation of a validated inhibitor.
The docking pose and thermal-shift assay experiments suggest
that Barbadin binds directly to the platform domain of
b2-adaptin and relies on residues that are also involved in the
interaction with b-arrestins. Indeed, the role of the benzyl-phenyl
moiety of Barbadin in mimicking Phe388 and Phe391 of
b-arrestin for binding b2-adaptin, is supported by the
observations that analogues lacking one of the two phenyl rings
(analogues A, B and compound 43) or altering the distance
and ﬂexibility between these rings (analogue C) showed lower
inhibitory action on the b-arrestin/b2-adaptin interaction.
Consistent with such a mode of binding that competes for the
binding of b-arrestin C-tail to the platform domain of b2-adaptin,
Barbadin inhibited the interaction between b2-adaptin and
b-arrestin in a reversible manner without affecting the recruit-
ment of b-arrestin to the receptor. Such selectivity may not be
surprising given that the targeted domain of interaction between
AP2 and b-arrestin is remote from the polar core of b-arrestin
that interacts with the receptors16,43. Furthermore, as the
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experiments.
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engagement of AP2 by b-arrestin follows the recruitment of
b-arrestin to the receptors24, blocking AP2 binding would not be
predicted to inﬂuence the initial b-arrestin binding to the
receptor. The topologically driven selectivity of Barbadin is also
illustrated by its lack of effect on the interaction between
b2-adaptin and other components of the CCPs such as clathrin
and epsin, which bind distinct sites on b2-adaptin compared
with b-arrestin. Consistent with the selectivity of Barbadin,
the formation of CCPs is not disturbed as demonstrated by
co-localization of AP2 and clathrin.
As predicted by its inhibitory action on the b-arrestin/
b2-adaptin interaction, Barbadin signiﬁcantly inhibited receptor
endocytosis as quantiﬁed by ﬂow-cytometry and BRET, and
imaged by ﬂuorescence microscopy experiments monitoring V2R
and b-arrestin cell surface localization. Although Barbadin did
not affect the recruitment of b-arrestin to the plasma membrane
upon V2R stimulation, it prevented its subsequent trafﬁcking to
endosomes. This inhibition resulted in a large fraction of the
b-arrestin accumulating at the cell surface and co-localizing
with AP2 and clathrin in CCPs. This ﬁnding suggests that the
b-arrestin-dependent accumulation of V2R-cargo into forming
CCPs is a multi-step process involving numerous interactions
with structural and endocytic accessory proteins of the coat
(Fig. 8). Interestingly, it also suggests that b-arrestin’s interaction
with b2-adaptin is essential in the maturation of clathrin-coated
vesicle-mediated internalization (for example, accumulation of
the V2R/b-arrestin complex into clathrin-coated vesicles at
plasma membrane and their ﬁnal invagination). In that respect,
the effect of Barbadin is reminiscent of the expression of an AP2
complex lacking the appendage domain of a-adaptin—which like
the b-appendage that binds b-arrestin for initiating GPCR
endocytosis, also recruits other regulatory/accessory proteins on
its platform domain for the internalization of other classes of
receptors—where it prevented the maturing and invagination of
CCPs13,44. The fact that Barbadin did not prevent the clustering
of receptor/b-arrestin complexes in CCPs is not unexpected
(Fig. 6a–c), considering that b-arrestin also forms low afﬁnity
interactions with clathrin through its carboxy tail45, and with AP2
via its m2 subunit through b-arrestin’s N-terminal domain46.
Indeed, when preventing the former interaction, the inhibitory
effect of Barbadin for clustering receptor/b-arrestin complexes in
CCPs was more readily observed. The robust Barbadin-promoted
inhibition of both agonist-promoted BRET between b2-adaptin-
YFP and b-arrestin-RlucII, as well as endocytosis for the b2AR,
V2R and AT1R support previous observations demonstrating
that the interaction between the carboxyl tail of b-arrestin and the
b2-adaptin subunit of AP2 is preponderant in the initial steps of
agonist-promoted internalization of many GPCRs17. The selective
action of Barbadin on endocytosis processes mediated by the
b-arrestin/AP2 complex was supported by its lack of effect on
the ligand-independent and ligand-promoted internalization of
transferrin and endothelin-1 receptors, respectively, which are
b-arrestin- and AP2-independent24,31,32. The demonstration that
Barbadin blocks receptor endocytosis, not only in engineered cells
heterologously expressing GPCRs but also in vascular smooth
cells endogenously expressing AT1R, paves the way for its use to
assess the role of the b-arrestin/b2-adaptin complexes in native
systems.
The observed effects of Barbadin on the ERK1/2 and cAMP
signalling activities of the receptors conﬁrm the role played
by endocytosis in the control of speciﬁc GPCR signalling
modalities9,11,12 and more particularly unambiguously demonstrate
the essential, but perhaps underappreciated, role of the b-arrestin/
AP2 interaction in this process. Barbadin completely blocks the
V2R-stimulated ERK1/2 activation conﬁrming the role of b-arrestin
in this signalling pathway for V2R (ref. 38), but the result also points
to a central role of endocytosis- and CCPs-mediated activation of
MAPK by the receptor/b-arrestin complex. This ﬁnding is consistent
with the emerging role of b-arrestin in CCPs for MAPK signalling,
which was described for the Bradykinin B2 receptor and recently
shown for the b1-adrenergic receptor47,48. Thus, inhibition of
b-arrestin signalling in both CCPs and endosomes (because
Barbadin prevented the trafﬁcking of receptor/b-arrestin
complexes to these intracellular compartments) most likely
contributes to the total blockade of V2R-mediated activation of
ERK1/2 by Barbadin. This inhibitory action of Barbadin on ERK1/2
Initiation Clustering/growth Scisssion Internalization and uncoating  
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Figure 8 | Model for the biogenesis of clathrin-coated pits (CCPs) and Barbadin’s effect on GPCRs endocytosis. (a) Initiation of CCPs formation
involves the association of AP2 with phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) at the plasma membrane (PM) and the recruitment of clathrin
to AP2 at sites of nucleation. Growth and stabilization of coated-vesicles requires the recruitment of additional AP2 and clathrin, and endocytic accessory
proteins like epsin (not shown here) and b-arrestins. Agonist-activated GPCR/b-arrestin complexes accumulate in CCPs through b-arrestin’s interactions
with AP2 (b2 and m subunits) and clathrin, stabilizing further the growing coated-vesicles. Stabilization of GPCR/b-arrestin complexes and the recruitment
of endocytic effectors like dynamin allows the matured coated-vesicles to commit for invagination and scission from the PM, which is followed by the
uncoating (that is, release of AP2 and clathrin) of internalizing vesicles. (b) In the presence of Barbadin, initiation of CCPs still occurs because clathrin and
AP2 are effectively recruited at sites of nucleation. Some receptor/b-arrestin complexes will still coalesce into nucleating CCPs through b-arrestin’s binding
with clathrin and its low afﬁnity interaction to AP2 (for example, via the m subunit). Because Barbadin prevents the interactions of b-arrestin with the
appendage domain on the b2-subunit of AP2, which prevents the stable formation of sufﬁcient GPCR/b-arrestin complexes in CCPs, the maturation of the
coated-vesicles is hampered, and receptor internalization impeded.
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activation cannot be attributed to a non-speciﬁc off-target effect of
the compound, on other components of the MAPK pathway since it
did not affect ERK1/2 activation promoted by the EGF receptor.
These results are therefore consistent with the notion that spatio-
temporal GPCR-stimulated ERK1/2 activation occurs following
clustering of receptor/b-arrestin in CCPs and endocytosis of the
complex in endosomes9,49.
The effect of Barbadin on the cAMP production stimulated by
both b2AR and V2R also provides new insights on the spatio-
temporal regulation of signalling as it brings strong support to the
emerging notion that GPCR-stimulated cAMP production
continues after endocytosis of Gs-coupled receptors13,50–56,
contrasting with the classical view that receptor endocytosis
contributes only to the termination of cAMP signalling. Sustained
interaction between receptor and b-arrestin at the plasma
membrane upon inhibition of endocytosis could also directly
contribute to the reduced cAMP accumulation by preventing
reactivation of the receptor at the plasma membrane. The effect
was speciﬁc to receptor-mediated cAMP production and did not
result from an off-target effect on Gs or the adenylyl cyclase since
Barbadin had no effect on the Gs activity as directly monitored by
BRET or cAMP generation resulting from a direct activation of
adenylyl cyclase by forskolin. The extension of endocytosis-
dependent cAMP production to the V2R is particularly
interesting given the fact that this receptor does not recycle
to the plasma membrane following endocytosis but is instead
retained for an extended period of time in endosomal
compartments before being targeted for degradation57. This
result excludes the possibility that the diminution of V2R-
promoted cAMP production following Barbadin treatment could
result from the accumulation of desensitized receptor at the
plasma membrane that cannot be replaced by re-sensitized ones
upon inhibition of endocytosis.
Barbadin is distinct from the existing endocytosis blockers as it
selectively interferes with the b2-adaptin/b-arrestin interaction
and thus solely blocks endocytic processes that are dependent on
the interaction between b-arrestin and the appendage domain of
the b-subunit of AP2. Existing pharmacological inhibitors such as
dynasore58, dynoles59 or dyngos30 inhibit all dynamin-dependent
endocytic pathways, while pitstop1/2 (ref. 28) inhibit both
clathrin-dependent and -independent endocytosis29. Although
we cannot rule out the possibility that Barbadin interacts with
other targets in cells, we found that it did not directly act on other
components of the clathrin endocytic machinery, nor on
important signalling effectors (for example, b-arrestin- and G
protein-dependent signalling promoted by GPCRs, cAMP
production by adenyl cyclase and MAPK activation promoted
by other receptors like EGFR) supporting a selective mode of
action. Barbadin’s selectivity of action on b-arrestin/AP2
interaction allows the dissection of the relative contribution of
this complex to the regulation of GPCRs endocytosis and
signalling, independently of other processes controlling cell
surface density, and thus represents a valuable addition to the
existing pharmacological toolbox60.
Methods
Materials. DMEM, FBS, penicillin, streptomycin, PBS and G418 were from
Wisent Inc. Cell culture plates and dishes were purchased from BD Biosciences.
Arginine vasopressin (AVP), isoproterenol (ISO), Angiotensin-II (AngII),
Epidermal Growth Factor (EGF), endothelin 1 (ET1), sigmacote, poly-L-ornithine
hydrobromide, 3-isobutyl-1-methylxanthine (IBMX), Triton X-100, mouse
monoclonal anti-b1- and b2-adaptins (AP1/2, clone 100/1, #A4450), rabbit
Anti-Flag antibody (#F7425), anti-Flag (M2, #F3165) and anti-mouse or anti-rabbit
HRP conjugated antibodies (#A9044 and #A9169, respectively) were from
Sigma-Aldrich. Poly-d-lysine was obtained from MatTek Corporation. Linear
polyethylenimine 25-kDa (PEI) was from Polysciences. BARR3978 antibody
against b-arrestin was previously described61. Phospho-p42/p44 (pERK1/2, #9106)
and p42/p44 (ERK1/2, #9102) antibodies were from Cell Signaling Technology.
Antibodies against clathrin heavy chain (Clone 23, 610499) and adaptin b (Clone
74, #610381) were obtained from BD Biosciences. Epsin1/2 rabbit antibody was
kindly provided by Peter McPherson (McGill University). Dithiobis succinimidyl
propionate (DSP) was from Pierce. Coelenterazine H, coelenterazine 400 A and
Prolume Purple were from Nanolight Technology. Mouse monoclonal anti-HA
antibody (HA.11) was purchased from Covance (#MMS-101 P). Anti-mouse Alexa
Fluor 647 secondary antibody (A-21463), ﬂuorescent transferrin conjugate (Alexa
Fluor 633, T23362), puromycin and salmon sperm DNA were bought from
Invitrogen. Pitstop2 was from Abcam (ab120687) and Dyngo (S7163) from
SelleckChem. cAMP dynamic-2 kit was from Cisbio. Costar v-bottom
polypropylene 96-wells plates were from Corning. White Optiplate 96-wells
microplates and 384-well Proxiplates were purchased from PerkinElmer. Lumitrac
200 384-wells plates were from Greiner Bio-one. X-treme GENE HP reagent was
from Roche and Strep-Tactin Sepharose beads from IBA Gmbh. b-arrestin1
C-terminal peptide (sequence: DDDIVFEDFARQRLKGMKDD) was synthesized
by Genscript, while CPM dye was purchased from ThermoFisher Scientiﬁc. Protein
concentration were determined using a detergent compatible protein assay kit from
Bio-Rad.
Differential scanning ﬂuorimetry was done in a RotorGeneQ from Qiagen.
Luminescence and BRET reading were performed in the Mithras LB 940
multidetector plate reader from Berthold Technologies. Cell surface expression of
receptors was analysed in a LSR II ﬂow cytometer from BD Biosciences.
Radioactivity was counted using a PerkinElmer Wizard 1470 automatic g-counter.
For microscopy, colocalization analyses were performed using Zen software from
Zeiss. Time-resolved ﬂuorescence resonance energy transfer was read in an Artemis
plate reader from Cosmo Bio USA.
Virtual screening. Virtual screening by docking has been performed on a
computer cluster of 10 Intel Core 2 Quad 2.6 GHz processors. The SD ﬁle of
the Myriascreen compounds collection (library number T990000) has been
requested to Sigma-Aldrich (www.sigmaaldrich.com). Canonicalization and
three-dimensional coordinates generation of the compounds were performed using
Chemaxon Standardizer, JChem 5.1.2 (www.chemaxon.com). Starting from the
b2-adaptin/b-arrestin co-crystal structure (PDB entry 2IV8), the AutoDockTools62
interface was used to prepare the binding site of b2-adaptin which was deﬁned as a
30-Å cubic box centred on the b-arrestin helical peptide bound to the b2-adaptin
ear platform subdomain. Docking was carried out using Autodock 4.0 (ref. 62) with
30 independent runs of simulation per compound docked. Autodock scoring
function was used to rank compounds by lowest energy. For visual inspection of
the best energy candidates, we chose to select any compounds within a range of
2.1 kcalmol 1 (s.e. of Autodock) from the best compound. The best 196 selected
compounds, and the docked Barbadin analogues were visually analysed using
PyMOL (PyMOL Molecular Graphics System, Version 1.4 Schro¨dinger, LLC) and
the MOE package (Molecular Operating Environment (MOE), 2012.10, Chemical
Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC,
Canada, H3A 2R7, 2012).
Compounds acquisition and technical consideration. The 52 small organic
compounds from the original screen were purchased from Sigma. Because
Barbadin was later discontinued by Sigma, it was then acquired from Otava
(#0129700278). Barbadin analogues were acquired from Enamine (see
Supplementary Table 1 for catalogue numbers). All compounds were solubilized in
100% DMSO at a 10mM stock concentration. To circumvent the possibility that
Barbadin adheres to plastic, all assays were carried out using tips, tubes and
96-wells plates coated with Sigmacote, then rinsed extensively with water.
Plasmids and constructs. Plasmids encoding myc-V2R (ref. 63), V2R-YFP
(ref. 63), HA-ETAR (ref. 64), HA-AT1R (ref. 65), b-arrestin1-RlucII (ref. 65),
b-arrestin2-RlucII (ref. 66), b-arrestin2-YFP (ref. 67), b-arrestin2-mCherry
(ref. 65), b2-adaptin-YFP (ref. 68), GST- b2-adaptin(592–937) (ref. 19),
ﬂag-b-arrestin1 (ref. 6), b2AR-RLucII (ref. 26), V2R-RLucII (ref. 26), AT1R-RLucII
(ref. 26), rGFP-CAAX (ref. 26) and rGFP-FYVE (ref. 26) were previously
described. b2-adaptin-mCherry was generated by replacing the YFP moiety of
b2-adaptin-YFP with that of the mCherry using the AgeI and BsrGI sites.
b2-adaptin-CFP was generated by replacing the YFP moiety of b2-adaptin-YFP
with that of the CFP from the pECFP vector. Clathrin light chain-YFP was
purchased from addgene (Cambridge, MA). The LIEF/AAEA substitution in
human b-arrestin2-YFP (b-arr2-DClath-YFP) was generated by complementation
PCR reaction, using the forward primer 5- GGACACCAACGCAGCTGAAGCC
GATACCAACTATGCC-3 with the reverse 5- TGGCGACCGGTGGATCCCG
GCAGAGTTGATCATCATAGTCG-3 primer containing the BamHI site, and the
reversed primer 5- TCGGCTTCAGCTGCGTTGGTGTCCACAGGGACATC-3
and forward primer 5-AGATCTCGAGCTCAAGCTTATGGGGGAGAAAC-3
containing the HindIII site. The PCR product from the ampliﬁed complementing
fragments was cloned into BamHI/HindIII sites by Gibson assembly (NEB). The
b2AR construct was generated by inserting a polymerase chain reaction (PCR)–
ampliﬁed fragment encoding human b2AR into a pcDNA3.1 vector, between
HindIII/XbaI. The b2-adaptin(700–937)-StrepTagII construct was generated by
inserting a PCR-ampliﬁed fragment encoding human b2-adaptin (residues from
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700 to 937) into a pRSETA vector (Invitrogen), between the BamHI and Acc65I
restriction sites. To generate HA-b2AR-Venus encoding plasmid, the Venus
sequence was ﬁrst PCR-ampliﬁed and introduced into the previously described
pIRESP-HA vector69. Then, the b2AR sequence was PCR-ampliﬁed and inserted
into pIRESP-HA-Venus vector by recombination using In-Fusion PCR Cloning Kit
from Clontech (Mountain View, CA). The HA-b2AR-Venus stable cell line was
generated by transfecting pIRESP-HA-b2AR-Venus in HEK293T followed by
polyclonal selection of expressing cells using 3 mgml 1 of puromycin. The
expression vectors pIREShygro3 and pIRESpuro3 were from Clontech (Mountain
View, CA). The plasmid encoding HA-V2R-Venus was made in two cloning steps.
First, HA-V2R gene was PCR-ampliﬁed from pcDNA3.1(þ )3HA-V2R plasmid
from Missouri S&T cDNA resource centre (Rolla, MO), keeping one HA tag and
removing the stop codon. The PCR product was then inserted in pIRESpuro3a
vector. Then, the Venus sequence was PCR-ampliﬁed and inserted in
pIRESpuro3a-HA-V2R. The resulting HA-V2R-Venus fusion sequence was then
inserted into pIREShygro3 vector, yielding pIREShygro3-HA-V2R-Venus plasmid.
The HA-V2R-Venus stable cell line was generated by transfecting pIREShygro3-
HA-V2R-Venus in HEK293T followed by polyclonal selection of expressing cells
using 100mgml 1 of hygromycin B. All constructs were veriﬁed by DNA
sequencing.
b2-adaptin deletion in HEK293 cells (CRISPR-b2Ad) were generated using the
CRISPR/Cas9 system PspCas9(BB)-2A-Puro (Px459v2) vector (Gift from Feng
Zhang: Addgene plasmid #62988)70 and the gRNA target sequences (50-GTA
TTTCACAACCAATAAAAA-30 and 50-GGTCTGGCTACCTGCAGTAA-30)
against the human AP2B1 gene (GenScript gRNA database). Each gRNA was
cloned into the Px459v2 vector, and both constructs were transfected in HEK293
cells using Lipofectamine 2000 according to the manufacturer’s instructions. The
next day, medium supplemented with puromycin (2 mgml 1) was added to cells
for 48 h and cells were serially diluted and plated in 96-wells plates for generating
individual colonies. Colonies were then veriﬁed for b2-adaptin expression by
western blot and by PCR genotyping using primers ﬂanking the deleted region.
Positive clone #5 (hereafter named CRISPR-b2Ad-LY5 cells) was selected.
Cell culture. HEK293T is the cell line in which BRET-based biosensors have been
developed in Dr Bouvier’s laboratory and this cell line was used for all the BRET
and FACS experiments. HEK293SL are a subclone derived from regular HEK293
cells (Ad5 transformed) and were selected in Dr Laporte’s laboratory. These cells
have a cobblestone appearance and a better adherence as compared with regular
HEK293T cells, making them more amenable to microscopy. HeLa is a cell line
expressing a higher level of native TfR, compared to HEK293T cells, and were
consequently used for monitoring TfR expression by FACS. HEK293T, HEK293SL
and HeLa cells were cultured in DMEM supplemented with 10% FBS, 100 units per
ml penicillin and streptomycin and incubated at 37 C in 5% CO2.
Primary rat aortic VSMCs were a gift from Dr. Marc Servant (Universite´ de
Montreal) and were used for endogenous AT1R internalization assay. These cells
were grown in DMEM/high glucose supplemented with sodium pyruvate, 10%
FBS, and 20mgml 1 gentamycin.
All cells were regularly tested for mycoplasma contamination (PCR
Mycoplasma Detection kit, abm, BC, Canada).
Bioluminescence resonance energy transfer (BRET) assays. HEK293T cells
stably expressing b2-adaptin-YFP (ref. 24) were cultured as aforementioned with
the addition of G418 in the supplemented DMEM. Forty-eight hours before the
experiments, 10 mg of total DNA (adjusted with salmon sperm DNA) was used to
transfect 6 106 cells per ml in 10-cm dishes using 25-kDa linear PEI as a
transfecting agent (3:1 PEI/DNA ratio). Cells stably expressing b2-adaptin-YFP
were transfected with either 250 ng of V2R, or 2.5 mg of b2AR, or 3.0 mg of AT1R
and with either 100 ng of b-arrestin1-RlucII or b-arrestin2-RlucII for the
compounds screen, the concentration-response curves, the one-point stimulation
experiments, as well as for the kinetics that monitors the interaction between
b2-adaptin and b-arrestin. To monitor b-arrestin recruitment to either V2R or
b2AR, HEK293T cells were transfected with 5 mg of V2R-YFP or 3 mg of b2AR-YFP
and 500 ng of b-arrestin1-RLucII or 120 ng of b-arrestin2-RLucII. For the pre-
screen experiment assessing compounds interference with BRET signals, HEK293T
cells were transfected with 100 ng of b-arrestin1-RlucII. On the day of the BRET
experiment, cells were washed, detached and resuspended in Tyrode’s buffer. Cells
(105 cells per well) were distributed in 96-wells microplates. DMSO or compounds
selected from the virtual screening were preincubated for 30min at indicated
concentrations, always keeping DMSO at 1% ﬁnal concentration in each well. Cells
were treated with AVP or ISO at the indicated times and concentrations, at room
temperature. Coelenterazine H (for YFP BRET acceptor) or coelenterazine 400A
(for GFP10 BRET acceptor) was added at a ﬁnal concentration of 2.5 mM ﬁve
minutes before measurements. Readings were collected with a Mithras LB 940
multidetector plate reader (Berthold Technologies) to integrate signals detected in
the 485/20 nm and 530/25 nm windows for the Renilla luciferase (RlucII) and YFP
light emissions, respectively, and in the 400/70 nm and 515/25 nm windows for the
RlucII and GFP10 light emissions, respectively. The BRET signal was determined
by calculating the ratio of the light intensity emitted by the YFP or GFP10 over the
light intensity emitted by the RlucII. Net BRET values were obtained by subtracting
the background BRET signals detected when RlucII was expressed alone. Ligand-
promoted BRET was calculated by subtracting the BRET ratio obtained in the
absence of agonist from the BRET ratio detected in its presence.
BRET imaging. HEK293SL cells seeded on poly-d-lysine-coated glass-bottom
35-mm culture dishes were transfected with 100 to 200 ng per dish of AT1R-RlucII
or V2R-RlucII, respectively, with either 400 ng per dish of rGFP-CAAX or 300 ng
per dish of rGFP-FYVE, using X-treme GENE HP reagent (Roche). Two days post
transfection, cells were washed once with 1ml of modiﬁed Hank’s balanced salt
solution (138mM NaCl, 5.33mM KCl, 0.44mM KH2PO4, 0.33mM Na2HPO4,
4.16mM NaHCO3, 1.0mM CaCl2, 1.0mM MgCl2, 10mM HEPES, pH 7.4) and set
on the microscope. BRET images were obtained using Nikon Ti-U microscope
equipped with  60 objective (Apochromat TIRF, NA 1.49, Nikon) and EMCCD
camera (EM N2 1024, Nu¨vu¨ Cameras) with ﬁlter changer (Lambda 10-2, Sutter
instrument). Prolume Purple (ﬁnal concentration of 10 mM) was added and images
were obtained using photon counting feature of the camera. The exposure time
of each image was 200msec. Images were obtained with or without a ﬁlter
corresponding to the BRET acceptor (480LP) wavelength. The ﬁlter was switched
after taking every 50 images, and the ﬁnal image was obtained by integrating
successive 500 images applying the same ﬁlter to the camera. BRET ratio images
were generated using pixel arithmetic functions of MetaMorph software version 7.8
(Molecular Devices) as follows: Pixel hue: BRET level calculated by dividing the
counts of acceptor luminescence images with total luminescence images, and
allocated to default rainbow hue (lowest in purple and highest in red); pixel
brightness: the value of donor images with auto brightness.
Protein puriﬁcation. Plasmid for b2-adaptin(700–937)-StrepTagII was
transformed in E. coli BL21 pLysS cells that were then grown at 37 C in TB
medium containing 100 mgml 1 ampicillin and 50mgml 1 chloramphenicol to
an absorbance at l¼ 600 nm (A600) of 0.6. Protein expression was induced
with 0.2mM IPTG and cells were grown overnight at 30 C. Pelleted cells were
resuspended in lysis buffer (100mM Tris–HCl, pH 8.0, 150mM NaCl, 1mgml 1
lysozyme, 5% glycerol, PMSF 0.5mM, TCEP 50 mM and 1mM EDTA) and frozen
at –80 C. For puriﬁcation, cells were thawed and lysed by mild sonication.
After cell debris removal by centrifugation, lysates were incubated with rinsed
Strep-Tactin Sepharose beads (IBA) at 4 C for one hour on a rotator. The protein
was subsequently eluted and puriﬁed further by passage over a sepharose column
(Bio-Rad) and a gel ﬁltration column. Protein was snap frozen in liquid nitrogen
and stored at  80 C for long-term storage.
Differential scanning ﬂuorimetry assay. The thermal denaturation of
b2-adaptin (residues 700–937, molecular weight 26.88 kDa) was monitored
by CPM (7-Diethylamino-3-(40-Maleimidylphenyl)-4-Methylcoumarin) dye
ﬂuorescence changes upon conjugation to the cysteines of b2-adaptin that become
exposed upon unfolding. The amount of 2.1 mg puriﬁed b2-adaptin was diluted in
100 ml ﬁnal volume using phosphate buffered saline (PBS) to the concentration of
0.78 mM. Samples containing 0.5mM Triton X-100 were incubated for 30min
without Barbadin (DMSO), with 10 mM, 33mM or 100mM Barbadin, or with 20mM
b-arrestin1 C-terminal peptide (sequence: DDDIVFEDFARQRLKGMKDD),
synthesized by Genscript, USA) before the addition of CPM dye (ThermoFisher
Scientiﬁc, Switzerland). CPM dye of 3mgml 1 in DMSO was diluted 1:80 in PBS
and 10 ml of the dilution was added to each sample to a ﬁnal concentration of
9.3 mM. Each sample was split into three 25 ml aliquots. The samples were then
heated from 30 C to 90 C at 6 Cmin 1 in a RotorGeneQ and the ﬂuorescence of
the CPM dye was monitored using 365 nm excitation and 460 nm emission.
RotorGeneQ Series Software was used for data analysis. The ﬁrst derivative of the
ﬂuorescence data was used to determine the melting temperatures.
Flow-cytometry for assessing receptor cell surface expression. For monitoring
V2R and b2AR cell surface expression, HEK293T cells stably expressing either
HA-V2R-Venus or HA-b2AR-Venus were seeded in 150mm dishes. For
monitoring ETAR cell surface expression, HEK293T cells were transfected with
HA-ETAR in 100mm dishes, using the PEI procedure previously described in the
methods. Forty-eight hours later, cells were harvested, rinsed with PBS, then
detached and resuspended in Tyrode’s buffer. Cells (1 106 cells per well) were
distributed in v-bottom 96-well plates. DMSO, Barbadin (100 mM), Pitstop2
(100 mM) and Dyngo-3a (30 mM) were preincubated for 30min (ﬁnal 1% DMSO
content in each well). Cells were treated at room temperature, in the absence or
presence of AVP (100 nM), ISO (10mM) or ET1 (10 nM) for the indicated times,
then put on ice for the rest of the experiment. Plates were quickly spun at 4 C
and supernatant from each well was removed using a vacuum line. Cells were
resuspended in Tyrode supplemented with 1% BSA (Tyrode/BSA) containing
mouse monoclonal anti-HA antibody (1:1,000) to label cell surface receptors. After
20min incubation, plates were quickly spun then resuspended in Tyrode/BSA
containing anti-mouse Alexa Fluor 647 secondary antibody (1:1,000). After 30min
incubation and protected from light, plates were quickly spun, and cells washed
and resuspended in Tyrode and kept on ice. Cells were analysed through a LSR II
ﬂow cytometer set to detect YFP and Alexa Fluor 647 nm in distinct channels
(Supplementary Fig. 8). For monitoring transferrin receptor surface expression,
HeLa cells were seeded in a 150mm dish and incubated for 48 h before being
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processed. One hour before the experiment, cells were serum-starved, then rinsed
with PBS and resuspended in Tyrode’s buffer. Cells were distributed in centrifuge
tubes (500 ml of resuspension per tube with 1 106 cells each). DMSO, Barbadin
(100 mM) or Pitstop2 (100 mM) were preincubated for 30min at room temperature,
then cells were put on ice for 10min. Cells were incubated with Alexa Fluor
633-conjugated transferrin (100 mgml 1) for 30min at 4 C in the dark, rinsed
with cold PBS and shifted to 37 C for 15min, except for a control tube that was
kept on ice. Cells were then pelleted, washed, acid-washed (0.1M glycine, 150mM
NaCl, pH 3), resuspended in Tyrode containing 1% BSA and analysed in a LSR II
ﬂow cytometer (Alexa Fluor 647 channel).
VSMC internalization assay. [125I]-AngII was prepared with the Iodogen
method, and speciﬁc activity was determined from self-displacement and
saturation experiments, as previously described65. Receptor internalization was
performed as described previously26. Brieﬂy, VSMCs were plated at a density of
B7 104 cells per well in poly-L-ornithine-coated 24-well plates. When cells were
conﬂuent (24–48 h after plating), they were starved in DMEM with 20mM HEPES
(DMEM-H) for 2 h before Barbadin treatment. Cells were incubated in either
DMSO or Barbadin (20 mM) for 30min at 37 C, before adding [125I]-AngII
(0.2 nM in 0.1% BSA binding buffer) for 15min at 37 C. Binding and
internalization of [125I]-AngII was terminated by rapidly rinsing the cells twice
with ice-cold PBS and then either rinsing once with ice-cold PBS to obtain total
binding, or with 50mM acetic acid in 150mM NaCl (pH 2.7) for 10min to
determine the internalized receptors (acid-resistant). Cells were solubilized in 0.5M
NaOH, 0.05% SDS and radioactivity was counted using a Wizard 1470 automatic
g-counter. Per cent receptor internalization was calculated from the ratio of
acid-resistant binding over total binding. Non-speciﬁc binding was determined in
the presence of 1 mM unlabelled AngII.
Fluorescence microscopy. For b-arrestin colocalization with b2-adaptin
experiments, HEK293T stably expressing human V2R cells were seeded in
35mm optical glass-bottom culture dishes with poly-L-lysine. Twenty-four hours
later, cells were transfected with 300 ng of b-arrestin2-mCherry, 400 ng of
b2-adaptin-YFP with pcDNA3.1 for up to 12 mg of total DNA using conventional
calcium phosphate co-precipitation method. For colocalization of b-arrestin2 with
b2-adaptin and clathrin, CRISPR-b2Ad-LY5 cells were seeded on coverslips coated
with poly-Ornithine and transfected with 2 mg of HA-V2R, 400 ng of b2-adaptin-
CFP, 300 ng of b-arrestin2-mCherry, 150 ng of clathrin-YFP and pcDNA3.1 for up
to 12mg of total DNA using lipofectamine 2000 according to the manufacturer’s
instructions. Media were changed the next day and experiment performed 48 h
post transfection. Cells were serum-starved for 30min, then pretreated with 10 mM
Barbadin or vehicle (DMSO) for an additional 30min before stimulation with 1 mM
AVP for 2.5min. Before mounting coverslips on slides, cells were ﬁrst washed in
PBS, then incubated for 10min in PBS-containing 4% Paraformaldehyde (PFA,
v/v). Images of live cells were collected on a Zeiss LSM-510 Meta laser scanning
microscope with a  63/1.4 oil objective lens using excitation/emission ﬁlter sets:
543 nm/560 nm (Long Pass) for mRFP, and 514 nm/530–600 nm (Band Pass) for
YFP. Images of ﬁxed cells were collected on a Zeiss LSM-780-NLO laser scanning
microscope with a  63/1.4 oil DIC M27 objective lens using 543 nm, 514 nm and
458 nm for mCherry, YFP and CFP excitation, and a GaAsP spectrum detector set
at 588–695 nm, 517–580 nm and 464–517 nm, respectively. Co-localization analysis
was performed using regions of interest (ROI) and analysed using Zen software.
GST-pulldown assays. Plasmid DNA for GST and GST-b2-adaptin(592–937)
were transformed in E. coli BL21 cells. Overnight cultures were grown in super-
broth medium supplemented with ampicillin (100 mg ml 1), diluted to an A600 of
0.4 in the same medium and grown for another 1 h 30 at 37 C to reach an A600 of
0.8 (log phase). Cultured cells were then induced with 0.1mM isopropyl-1-thio-b-
D-galactopyranoside (IPTG) for 5 h at 30C. Cells were then pelleted, washed once
with PBS and resuspended in PBS containing 1mM phenylmethylsulfonyl ﬂuoride
(PMSF), 2mgml 1 lysozyme and incubated for 15min on ice. Cells were lysed by
immediately adding Triton X-100 (1% v/v) followed by two freeze-thaw cycles in
liquid nitrogen. Solubilized cells were sonicated (3 15 s) on ice and centrifuged at
13,000 r.p.m. for 10min. Glutathione-sepharose beads were added to the super-
natant and gently shaken at 4 C for 2 h. Beads were washed three times with cold
PBS containing 1% Triton X-100, then three times with cold PBS. Protein con-
centration was determined using a detergent compatible protein assay kit, and the
integrity of the fusion proteins was analysed by SDS-polyacrylamide gel electro-
phoresis and by Coomassie staining. To prepare cell lysate, HEK293T (1.2 106)
were plated in 100mm dishes and transfected 24 h later with 5 mg of Flag-b-
arrestin1 and pcDNA3.1 (to a total of 12 mg) using conventional calcium phosphate
co-precipitation method. After overnight incubation, transfection medium was
replaced with fresh MEM. Twenty-four hours later, cells were washed with PBS and
lysed in a glycerol buffer containing 1mM PMSF, 25 mgml 1
leupeptin, 2.5 mgml 1 aprotinin and 1mM pepstatin. Cell lysates were cleared
by centrifugation (14,000 r.p.m. for 15min). Seven micrograms of GST or
GST-b2-adaptin(592–937) were incubated for 1 h at RT with or without Barbadin
(200 mM) in 100 ml PBS, then 100 ml of cell lysate was added and left 2 h at 4 C on a
Nutator. Beads were spun and washed ﬁve times in glycerol buffer and resuspended
in SDS sample buffer (8% SDS, 25mM Tris–HCl, pH 6.5, 10% glycerol, 5%
2-mercaptoethanol, 0.003% bromophenol blue). Proteins were resolved by
electrophoresis on a 10% gel, transferred onto nitrocellulose and analysed by
western blot using mouse monoclonal anti-Flag (1:1,000) and anti-clathrin
(1:1,000) antibodies, or stained with Coomassie blue for GST protein detection.
Co-immunoprecipitation. Co-immunoprecipitation experiments were performed
as previously described67. Brieﬂy, HEK293SL cells transfected with 3 mg V2R and
500 ng of Flag-b-arrestin2 were serum-starved for 30min, and then pretreated for
20min with DMSO or Barbadin (50 mM) before stimulation with AVP (1 mM) for
2.5 and 5.0min. Stimulation was stopped by adding dithiobis succinimidyl
propionate (DSP) to cells (2mM). Cells were then washed in 50mM Tris–HCl
(pH 7.5) and lysed in RIPA buffer (50mM Tri–HCl, pH 7.4, 1% NP-40 (v/v), 0.5%
Na-Deoxycholate (w/v), 0.1% sodium dodecyl sulfate (w/v), 150mM NaCl, 2mM
EDTA, 50mM NaF). Total cell lysates (TCL) were immunoprecipitated with
anti-AP1/2 antibody (25mg) and then analysed by western blot using anti-adaptin
(BD Biosciences, 1:1,000) for TCL and AP1/2 (1:1,000) for IP samples, anti-epsin
(1:500) or anti-Flag antibodies (1:1,000), and secondary HRP antibodies
(1:7,000)61. AP1/2 antibody has been reported to detect both the b1 and b2
subunits, which have different sizes. However, in HEK293SL, AP1/2 antibody
mainly immunoprecipitated and recognized a protein of B105 kDa
(Supplementary Fig. 9), which we validated to be immune-reactive for b2-adaptin
using a speciﬁc antibody against this subunit (BD Bioscience). This was conﬁrmed
using b2-adaptin knock out cells (CRISPR-b2Ad-LY5, Supplementary Fig. 7).
cAMP assay. Intracellular cAMP accumulation was measured using the cAMP
dynamic-2 kit, a competitive immunoassay based on homogeneous time-resolved
ﬂuorescence technology. HEK293T cells, as well as HEK293T stably expressing
either V2R or b2AR were starved for 4 h in DMEM before being processed. Cells
were rinsed once in PBS and once in cAMP-assay buffer (PBS with 1% BSA and
0.5mM IBMX), detached and resuspended in the same buffer, then seeded (4 104
cells per well) in 96-well microplates. For concentration-response curves, cells were
pretreated or not (DMSO) with Barbadin at the indicated concentrations for
30min (1% DMSO ﬁnal concentration in each well), then treated at room
temperature with vehicle, AVP (100 nM), ISO (1 mM) or forskolin (10mM) for
15min and put at  80 C for 1 h. For kinetics experiments, cells were pretreated
or not (DMSO) with Barbadin (50 mM) for 30min, then treated with vehicle,
AVP (100 nM) or ISO (1 mM) for the indicated times, and put at  80 C for 1 h.
Once thawed, cells (4 103 cells per well) were transferred in 384-well plates
and incubated with cAMP labelled with the dye d2, and anti-cAMP antibody
labelled with Cryptate according to the manufacturer’s protocol. Reading of the
homogeneous time-resolved ﬂuorescence signal was performed on an Artemis plate
reader.
ERK1/2 activation assay. HEK293T cells (105 cells per well) were seeded in a
6-well plate and transfected with a V2R encoding plasmid. Forty-eight hours post
transfection, cells were serum-starved for 30min in MEM containing 20mM
HEPES, treated with either DMSO or Barbadin (50 mM) for 10min, and then
stimulated with vehicle (MEM), AVP (1 mM) or epidermal growth factor (EGF,
100 ngml 1) for the indicated times. Treatment was stopped on ice with cold PBS,
and cells were solubilized in  2 laemmli buffer (250mM Tris–HCl pH 6.8, 2%
SDS (w/v), 10% glycerol (v/v), 0.01% bromophenol blue (w/v) and 5%
b-mercaptoethanol (v/v)). Lysates were resolved on a 10% SDS–PAGE and
analysed by western blot using anti-phospho-ERK1/2 (1:1,000) and anti-total-
ERK1/2 (1:2,000). Signals from western blots were determined by densitometry
analysis using the Image J software (NIH).
Data and statistical analyses. Nonlinear regression analysis of the concentration-
response and kinetics curves and statistical analyses (assuming similar variance
between groups) were performed with GraphPad Prism software. For the
concentration-response curves the ‘log inhibitor versus response–three parameters
(Hill slope¼  1)’ ﬁtting was used. Student’s t-test or one-way analysis of variance
(ANOVA) and Tuckey’s post-hoc tests were performed as appropriate (see ﬁgure
legends). Two-way ANOVA and Bonferroni’s post-hoc tests (comparison between
all groups) were used for statistical analysis of western blot signals for ERK and
co-immunoprecipitation assays, as well as for compounds’ effect on receptor
endocytosis kinetics by FACS. Colocalization of signals from microscopy
experiments was analysed using Pearson’s correlation coefﬁcient.
Data availability. The authors declare that all data supporting the ﬁndings in this
study are presented within the article and its Supplementary Information ﬁles and
available from the corresponding author upon request. Amino acid sequences for
hb2-adaptin are provided in Supplementary Data 1.
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